Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction
- PMID: 32868137
- DOI: 10.1016/j.eururo.2020.08.018
Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction
Abstract
Background: In the algorithm of treatment of benign prostatic obstruction (BPO), the shift from medical therapy to surgery is steep in terms of invasiveness. Recently, a lively interest has developed on alternative micro-invasive options. Transperineal interstitial laser ablation (TPLA) was recently proposed for BPO treatment.
Objective: This work aims to illustrate feasibility, efficacy and safety profile of TPLA in BPO treatment.
Design, setting, and participants: We prospectively analyzed the results of TPLA performed between September 2018 and March 2019 for LUTS due to BPO, in men with prostate volume <100 ml.
Surgical procedure: TPLA was performed in OR, under local anesthesia, using Soracte Lite-EchoLaserX4. Diode laser light is conveyed through 300 μm optical fibers introduced transperineally by 21 Ga needles and placed at a security distance from urethra and bladder neck. EchoLaser Smart Interface eases needle positioning and increases the safety.
Measurements: The primary endpoint was the variation of Qmax and IPSS at 1, 3 and 6 months. We also assessed the ejaculatory function and recorded complications. These outcomes were further investigated at 12 months by phone call.
Results and limitations: 21 men with prostate volume of 43.5 ± 8.5 ml underwent TPLA. All were discharged after 24 h, keeping the transurethral catheter for 8.7 ± 2.5d. At one month all patients but one discontinued medical therapy, showing significant advantage in Qmax (+3.4 ± 5.7 ml/s; p < 0.01) and IPSS (-5.6 ± 7.0; p < 0.01). Functional results were still progressing at 6 months, with Qmax (+4.7 ± 6.0 ml/s; p < 0.01) and IPSS improvement (-13.1 ± 4.7; p < 0.01). The ejaculatory function was preserved as the MSHQ-EjD increased (p < 0.05). The only complication was a prostatic abscess, treated with transperineal drainage and antibiotic.
Conclusions: TPLA is a micro-invasive treatment for BPO showing good functional and safety outcomes.
Patient summary: This work illustrates the results of TPLA to treat LUTS due to BPO, showing high efficacy, preservation of the ejaculation, and low complication rate.
Keywords: Benign prostatic obstruction; Echolaser; Ejaculation-sparing; Interstitial laser; Lower urinary tract symptoms; Micro-invasive treatment; Transperineal laser ablation.
Copyright © 2020 European Association of Urology. All rights reserved.
Comment in
-
Transperineal Interstitial Laser Ablation of the Prostate, A Novel Option for Minimally Invasive Treatment of Benign Prostatic Obstruction.Eur Urol. 2021 Nov;80(5):673-674. doi: 10.1016/j.eururo.2021.08.019. Epub 2021 Sep 6. Eur Urol. 2021. PMID: 34503881 No abstract available.
-
Reply to Davide Rosati, Riccardo Lombardo, Cosimo De Nunzio, Constantino Leonardo, and Andrea Tubaro's Words of Wisdom re: Transperineal Interstitial Laser Ablation of the Prostate, A Novel Option for Minimally Invasive Treatment of Benign Prostatic Obstruction. Eur Urol 2021;80:673-4.Eur Urol. 2022 Apr;81(4):e100-e101. doi: 10.1016/j.eururo.2021.12.037. Epub 2022 Jan 31. Eur Urol. 2022. PMID: 35101305 No abstract available.
-
Benign Prostatic Hyperplasia.J Urol. 2022 Jun;207(6):1323-1325. doi: 10.1097/JU.0000000000002509. Epub 2022 Mar 18. J Urol. 2022. PMID: 35300513 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
